Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies
if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the
same subfield and year (this is the minimum needed to enter the top 1%, not the average
within it), or reaches the top citation threshold in at least one of its specific research
topics.
Phase II Study of Cetuximab As First-Line Single-Drug Therapy in Patients With Unresectable Squamous Cell Carcinoma of the Skin
2011334 citationsE. Maubec, Peter Petrow et al.Journal of Clinical Oncologyprofile →
Author Peers
Peers are selected by citation overlap in the author's most active subfields.
citations ·
hero ref
This map shows the geographic impact of B. Crickx's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by B. Crickx with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites B. Crickx more than expected).
This network shows the impact of papers produced by B. Crickx. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by B. Crickx. The network helps show where B. Crickx may publish in the future.
Co-authorship network of co-authors of B. Crickx
This figure shows the co-authorship network connecting the top 25 collaborators of B. Crickx.
A scholar is included among the top collaborators of B. Crickx based on the total number of
citations received by their joint publications. Widths of edges
represent the number of papers authors have co-authored together.
Node borders
signify the number of papers an author published with B. Crickx. B. Crickx is excluded from
the visualization to improve readability, since they are connected to all nodes in the network.
Maubec, E., Peter Petrow, Isabelle Scheer-Senyarich, et al.. (2011). Phase II Study of Cetuximab As First-Line Single-Drug Therapy in Patients With Unresectable Squamous Cell Carcinoma of the Skin. Journal of Clinical Oncology. 29(25). 3419–3426.334 indexed citations breakdown →
Maubec, E., Pierre Duvillard, Valérie Velasco, B. Crickx, & Marie‐Françoise Avril. (2005). Immunohistochemical analysis of EGFR and HER-2 in patients with metastatic squamous cell carcinoma of the skin.. PubMed. 25(2B). 1205–10.79 indexed citations
Descamps, V., Xavier Duval, B. Crickx, et al.. (1999). Global improvement of systemic scleroderma under long-term administration of octreotide.. PubMed. 9(6). 446–8.12 indexed citations
Capésius, C, et al.. (1992). [Histiocytofibroma and basal cell carcinoma].. PubMed. 119(1). 31–4.1 indexed citations
19.
Tousignant, J, M Grossin, B. Crickx, & S Belaïch. (1991). [Paget's disease of the nipple associated with epidermal basaloid hyperplasia simulating basal cell carcinoma].. PubMed. 118(3). 211–4.1 indexed citations
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive
bibliographic database. While OpenAlex provides broad and valuable coverage of the global
research landscape, it—like all bibliographic datasets—has inherent limitations. These include
incomplete records, variations in author disambiguation, differences in journal indexing, and
delays in data updates. As a result, some metrics and network relationships displayed in
Rankless may not fully capture the entirety of a scholar's output or impact.